CJC-1295 with DAC vs without DAC
CJC-1295 without DAC (also called Mod GRF 1-29) has a ~30-minute half-life and preserves the natural pulsatile GH rhythm. CJC-1295 with DAC attaches a Drug Affinity Complex that extends the half-life to ~8 days, producing a flat elevated GH baseline instead of pulses. The choice is pulsatility vs steady-state — and pulsatility is what you usually want.
Without DAC is the right choice for almost every research protocol — the pulsatile GH rhythm is what most research questions want to preserve. With DAC is a narrow tool for protocols that specifically want a flat, elevated GH baseline, which is uncommon. Defaulting to 'with DAC' is the most common practitioner mistake.
Contender A
CJC-1295 with DAC
Also: CJC-DAC
GHRH analog with Drug Affinity Complex — binds albumin, extending half-life from ~30 min to ~8 days. Produces sustained GHRH signaling.
- Half-life
- ~8 days
- Primary use
- Sustained GH elevation research
- Dose range
- 1-2 mg weekly
- Cost tier
- $$ · Moderate sourcing cost
Contender B
CJC-1295 without DAC
Also: Mod GRF 1-29
Modified GHRH (1-29) analog — same receptor binding as DAC version but without albumin-binding complex. Clears fast, preserves pulsatility.
- Half-life
- ~30 min
- Primary use
- Pulsatile GH research (stacks with Ipam)
- Dose range
- 100 mcg per dose, 1-3x daily
- Cost tier
- $ · Low sourcing cost
Detailed Comparison
10 attributes side-by-side. Highlighted rows show where one tool has a clear structural edge.
| Attribute | CJC-DAC | Mod GRF 1-29 | Edge |
|---|---|---|---|
Half-life Neither is objectively better — depends on whether you want pulsatility. | ~8 days | ~30 min | Tie |
Preserves pulsatile GH rhythm | No — flattens it | Yes | Mod GRF 1-29 |
Dosing cadence | Weekly | 1-3x daily | CJC-DAC |
Stacks with Ipamorelin | Works but synergy blunted | Optimal | Mod GRF 1-29 |
Risk of pituitary downregulation | Higher (steady signaling) | Lower (pulsatile) | Mod GRF 1-29 |
IGF-1 elevation magnitude | Large and sustained | Moderate, pulsatile | CJC-DAC |
Side-effect profile | Edema, tingling more common | Very clean | Mod GRF 1-29 |
Research-sourcing cost | Higher per mg | Lower per mg | Mod GRF 1-29 |
Protocol complexity | Simpler (weekly) | More disciplined (daily) | CJC-DAC |
Mirrors endogenous biology | No | Yes | Mod GRF 1-29 |
Practitioner Notes
Sourced from practitioner-validated protocols — not PubMed abstracts.
The practitioner consensus is heavily skewed toward without-DAC. The reason: endogenous GH is pulsatile by design, and pulsatile signaling prevents pituitary downregulation. A flat 8-day GH elevation (what with-DAC produces) trains the pituitary to expect a constant signal, and the physiological response dulls over weeks. Without-DAC preserves the natural rhythm.
With-DAC still has a place — research protocols specifically interested in sustained GH elevation (not pulses) use it. Edema and tingling are more common on with-DAC because the sustained GH level pushes water retention and mild nerve effects. Researchers who report 'I couldn't tolerate CJC-1295' are almost always on the with-DAC version.
The cost asymmetry is real but rarely decisive. Without-DAC is cheaper per mg but needs daily dosing; with-DAC is more expensive per mg but only needs weekly injection. Over a 12-week protocol the total cost is similar. The decision is mechanistic, not financial.
Stacking & Switching
Can these be combined? Should you switch from one to the other? Titration considerations.
Stack compatibility: See the “Stacks well” or “Stack compatibility” row in the comparison table above. When the edge column shows Tie, both compounds run together cleanly. When one compound dominates, check the protocol notes for the specific stacking pattern practitioners use.
Switching protocol: The general pattern across practitioner protocols: hold the current dose stable, introduce the new compound at its lowest titration step, run both for a 1-2 week cross-over window, then taper the original. Abrupt switches produce rebound effects as the original compound's steady state clears.
Half-life math: DoseCraft's PK-aware AI models half-life decay and stack overlap across every pairing above. The 20x20 interaction matrix flags contraindications automatically — no manual math, no overlapping-signal blindspots.
Frequently Asked Questions
Indexed for SERP FAQPage rich results.
Which should I pick?
+
Without DAC, in almost all protocols. Pulsatility is what endogenous GH biology expects, and the stack synergy with Ipamorelin only works properly with the fast-clearing version.
What is DAC?
+
Drug Affinity Complex — a structural modification that binds the peptide to albumin in circulation, dramatically extending half-life. In CJC-1295's case, from ~30 min to ~8 days.
Why do some protocols still use with-DAC?
+
Research questions that specifically want sustained GH elevation (not pulses) — usually narrow use cases. Convenience (weekly vs daily) is also a real factor.
Does with-DAC cause more side effects?
+
Yes, consistently in practitioner reports — edema, tingling, and numbness are more common because the sustained GH elevation drives water retention and mild peripheral nerve effects.
Does without-DAC require refrigeration?
+
Post-reconstitution, yes. Both versions need cold storage once mixed. Without-DAC is more fragile because the shorter peptide structure is less stabilized.
Related Comparisons
GH Axis
Ipamorelin vs CJC-1295
Ipamorelin mimics ghrelin and triggers a GH pulse via the growth hormone secretagogue receptor. CJC-1295 is a GHRH analog that extends and amplifies the natural GH pulse window. They hit different receptors and produce a bigger, cleaner GH pulse when stacked than either does alone.
ReadGH Axis
Ipamorelin vs Sermorelin
Ipamorelin is a selective ghrelin-receptor agonist (GHS class). Sermorelin is a GHRH (1-29) analog and the oldest research-grade GHRH tool. They act on different receptors in the GH axis — Ipamorelin triggers a new pulse, Sermorelin extends the natural GHRH-driven pulse. Stacking them is more common than comparing them.
ReadHealing
BPC-157 vs TB-500
BPC-157 is a pentadecapeptide derived from gastric juice with strong localized healing signals, especially in GI and tendon research. TB-500 is a fragment of Thymosin Beta-4 with systemic actin-binding activity driving cell migration, angiogenesis, and broad tissue recovery. Half-lives and delivery profiles are very different; so are their niches.
ReadTrack Your Protocol with PK-Aware AI
Compound choice is step one. DoseCraft models half-life decay, stack overlap, and titration paths across 90+ peptides — a pharmacokinetic reasoning layer on top of practitioner-validated protocols.
Track your protocol with PK-aware AI in DoseCraftResearch-only disclaimer: This comparison is for research and educational purposes only. Peptides referenced are sold for research use by third-party suppliers. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed physician before acting on any peptide protocol information.